Ribupatide
Ribupatide (HRS9531, KAI-9531)
Also known as: HRS9531, KAI-9531
A once-weekly GLP-1/GIP dual agonist in the tirzepatide class that delivered 19.2% weight loss at 48 weeks in a Chinese Phase 3 trial and is now in global pivotal studies at higher doses.
Overview
Ribupatide is Hengrui's dual incretin agonist, licensed outside China to Kailera Therapeutics. In the 567-patient HRS9531-301 trial, the 6 mg dose produced 19.2% mean weight loss at 48 weeks with no plateau and adverse-event discontinuation of only 0.7% to 1.4%. The drug has been filed with China's regulator, and the global KaiNETIC Phase 3 program that began in January 2026 is testing 8 mg and 10 mg doses.
Mechanism of action
Simultaneous agonism of the GLP-1 and GIP receptors, the same dual-incretin approach as tirzepatide.
Key studies & citations
- Human2025
HRS9531 in adults with obesity: Phase 3 in China (HRS9531-301)
19.2% mean weight loss at 48 weeks on 6 mg.
ClinicalTrials.gov NCT06396429 - Human2025
Hengrui and Kailera report positive topline Phase 3 obesity data for HRS9531
Discontinuation for adverse events of 0.7% to 1.4%.
Kailera press release - Human2026
KaiNETIC 1: global Phase 3 of KAI-9531
Tests 8 mg and 10 mg doses outside China.
ClinicalTrials.gov NCT07284875
Frequently asked questions
Is ribupatide better than tirzepatide?
Its 48-week Phase 3 number (19.2%) is higher than tirzepatide's at the same timepoint, but the trials enrolled different populations and there is no head-to-head comparison.